赛诺菲的Beyfortus显示出两个RSV季节的住院效益

2026-02-17 17:07

Sanofi (SNY) Monday said that a study published in The Lancet Infectious Diseases showed infants immunized with Beyfortus had 85.9% fewer RSV-related LRTI hospitalizations in the first season and 55.3% fewer hospitalizations in the second season.
The NIRSE-GAL prospective real-world study in Galicia, Spain, included 11,796 immunized infants (94.4% coverage) and found statistically significant reductions in hospitalizations beyond the initial RSV season.
"This universal RSV immunization program with Beyfortus showed decreased RSV-related hospitalizations and outpatient illness burden during the first season, with persistent impact seen on RSV hospitalizations through the second season,” said Federico Martinón-Torres, Head of Pediatrics at Santiago University Hospital in Spain.
Beyfortus is approved for prevention of RSV lower respiratory tract disease in infants, with data to be presented at the RSVVW '26 conference; results reinforce the public health value of universal infant immunization programs.

More on Sanofi